| Overview |
| bs-1619R-Cy3 |
| Smad1 + Smad5 Polyclonal Antibody, Cy3 Conjugated |
| FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Smad 5 |
| 361-465/465 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4090, 4086 |
| Cytoplasm, Nucleus |
| Mothers against decapentaplegic homolog 5; SMAD5; Mothers against decapentaplegic homolog 1; SMAD1 |
| Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD5 is a receptor-regulated SMAD (R-SMAD). Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD1 is a receptor-regulated SMAD (R-SMAD). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. May act synergistically with SMAD4 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. |
| Application Dilution |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz